 The aim of this study was to investigate the mucosal gene expression defects associated with active Crohns disease CDand ulcerative colitis UC, and to study the effect of infliximab induced downregulation of inflammation and mucosal healing on these abnormalities, using whole genome gene expression microarray technology on endoscopic-derived intestinal mucosal biopsies from control individuals and patients with active IBD, and this before and after their first infliximab treatment. 